ホーム>>Signaling Pathways>> Apoptosis>>Raddeanin A

Raddeanin A

カタログ番号GC19607

ラデアニン A は、アネモネ ラデアナの天然のトリテルペノイド サポニン成分であり、抗がん作用があります。ラデアニン A は、ROS/JNK および NF-κB シグナル経路を介してヒト骨肉腫に抗がん効果を発揮します。

Products are for research use only. Not for human use. We do not sell to patients.

Raddeanin A 化学構造

Cas No.: 89412-79-3

サイズ 価格 在庫数 個数
5mg
$114.00
在庫あり
10mg
$194.00
在庫あり
20mg
$330.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway[1][2][3][4].

[1]. Ma B, et al. Raddeanin A, a natural triterpenoid saponin compound, exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway. Toxicol Appl Pharmacol. 2018 Aug 15;353:87-101. [2]. Guo SS, et al. Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. 3.411World J Gastroenterol. 2019 Jul 14;25(26):3380-3391. [3]. Xia H, et al. Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer. J Cell Mol Med. 2019 May;23(5):3656-3664. [4]. Meng C, et al. Raddeanin A Induces Apoptosis and Cycle Arrest in Human HCT116 Cells through PI3K/AKT Pathway Regulation In Vitro and In Vivo. Evid Based Complement Alternat Med. 2019 May 26;2019:7457105.

レビュー

Review for Raddeanin A

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Raddeanin A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.